Antibodies specific for CLL-1

1. An antibody that binds to human C-type lectin like molecule 1 (CLL-1), said antibody selected from the group consisting of:

an antibody comprising heavy chain complementarity determining regions (CDRs) of SEQ ID NOs:51, 59, and 67, and light chain CDRs of SEQ ID NOs:75, 83, and 91;

an antibody comprising heavy chain CDRs of SEQ ID NOs:52, 60, and 68, and light chain CDRs of SEQ ID NOs:76, 84, and 92; and

an antibody comprising heavy chain CDRs of SEQ ID NOs:53, 61, and 69 and light chain CDRs of SEQ ID NOs:77, 85, and 93.

2. The antibody of claim 1 , wherein the antibody is selected from isotype classes IgA, IgD, IgE, IgG, and IgM.

3. The antibody of claim 1 , wherein the antibody is selected from humanized, human, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, and grafted antibodies.

4. The antibody of claim 1 , wherein the antibody is a bispecific antibody.

5. The antibody of claim 1 , wherein the antibody is a chimeric antibody.

6. The antibody of claim 1 , wherein the antibody is isolated.

7. The antibody of claim 1 , wherein the antibody is an antibody fragment selected from Fab, F(ab′)2, Fv, scFv, Fd and dAb.

8. The antibody of claim 1 , wherein the antibody is conjugated to a detectable moiety.

9. The antibody of claim 1 , wherein the antibody is conjugated to a fluorescent dye.

10. The antibody of claim 1 , wherein the antibody is associated with a nanocarrier.

11. The antibody of claim 1 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 51, 59, and 67, and light chain CDRs of SEQ ID NOs: 75, 83, and 91.

12. The antibody of claim 11 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 6.

13. The antibody of claim 11 , wherein the antibody is selected from an immunoglobulin, antibody conjugate, or antibody fragment.

14. The antibody of claim 11 , wherein the antibody is humanized.

15. The antibody of claim 11 , wherein the antibody is a fusion protein.

16. The antibody of claim 11 , wherein the antibody is an scFv fusion protein.

17. The antibody of claim 11 , wherein the antibody comprises a chimeric antibody in which the constant region, is replaced so that the antigen binding site is linked to a different effector function.

18. The antibody of claim 11 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

19. The antibody of claim 1 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 52, 60, and 68, and light chain CDRs of SEQ ID NOs: 76, 84, and 92.

20. The antibody of claim 19 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 10.

21. The antibody of claim 19 , wherein the antibody is selected from an immunoglobulin, antibody conjugate, or antibody fragment.

22. The antibody of claim 19 , wherein the antibody is humanized.

23. The antibody of claim 19 , wherein the antibody is a fusion protein.

24. The antibody of claim 19 , wherein the antibody is an scFv fusion protein.

25. The antibody of claim 19 , wherein the antibody comprises a chimeric antibody in which the constant region, is replaced so that the antigen binding site is linked to a different effector function.

26. The antibody of claim 19 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

27. The antibody of claim 1 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 53, 61, and 69 and light chain CDRs of SEQ ID NOs: 77, 85, and 93.

28. The antibody of claim 27 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.

29. The antibody of claim 27 , wherein the antibody is selected from an immunoglobulin, antibody conjugate, or antibody fragment.

30. The antibody of claim 27 , wherein the antibody is humanized.

31. The antibody of claim 27 , wherein the antibody is a fusion protein.

32. The antibody of claim 27 , wherein the antibody is an scFv fusion protein.

33. The antibody of claim 27 , wherein the antibody comprises a chimeric antibody in which the constant region, is replaced so that the antigen binding site is linked to a different effector function.

34. The antibody of claim 27 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

35. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

36. The pharmaceutical composition of claim 35 , wherein the antibody is humanized.

37. The pharmaceutical composition of claim 35 , wherein the antibody binds to human C-type lectin like molecule 1 (CLL-1) and comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 51, 59, and 67, and light chain CDRs of SEQ ID NOs: 75, 83, and 91.

38. The pharmaceutical composition of claim 37 prepared for parenteral or intravenous administration.

39. The pharmaceutical composition of claim 37 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

40. The pharmaceutical composition of claim 37 , wherein the antibody is conjugated to a cytotoxic agent selected from a saporin, a taxane, a vinca alkaloid, an anthracycline, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine dimer and a platinum-based agent.

41. The pharmaceutical composition of claim 35 , wherein the antibody binds to human C-type lectin like molecule 1 (CLL-1) and comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 52, 60, and 68, and light chain CDRs of SEQ ID NOs: 76, 84, and 92.

42. The pharmaceutical composition of claim 41 prepared for parenteral or intravenous administration.

43. The pharmaceutical composition of claim 41 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

44. The pharmaceutical composition of claim 41 , wherein the antibody is conjugated to a cytotoxic agent selected from a saporin, a taxane, a vinca alkaloid, an anthracycline, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine dimer and a platinum-based agent.

45. The pharmaceutical composition of claim 35 , wherein the antibody binds to human C-type lectin like molecule 1 (CLL-1) and comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 53, 61, and 69, and light chain CDRs of SEQ ID NOs: 77, 85, and 93.

46. The pharmaceutical composition of claim 45 prepared for parenteral or intravenous administration.

47. The pharmaceutical composition of claim 45 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

48. The pharmaceutical composition of claim 45 , wherein the antibody is conjugated to a cytotoxic agent selected from a saporin, a taxane, a vinca alkaloid, an anthracycline, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine dimer and a platinum-based agent.

49. The pharmaceutical composition of claim 35 in unit dosage form.

50. A method of determining whether a cell expresses C-type lectin like molecule 1 (CLL-1), comprising,

contacting the antibody of claim 1 with the cell; and

detecting the binding of the antibody to the cell, wherein binding of the antibody to the cell indicates that the cell expresses CLL-1; and

determining whether the cell expresses CLL-1.

51. The method of claim 50 , wherein the cell is in a biological sample from an individual that includes hematopoietic cells.

52. The method of claim 50 , further comprising determining whether the cell expresses CD34 or CD38.

53. A method for killing a cell expressing C-type lectin like molecule 1 (CLL-1), comprising contacting the antibody of claim 1 with the cell, wherein the antibody:

i. comprises a constant domain that induces cell dependent cytotoxicity (CDC) or antibody dependent cell-mediated cytotoxicity (ADCC); or

ii. is conjugated to a cytotoxic compound;

thereby killing the cell.

54. The method of claim 53 , wherein the contacting comprises administering the antibody to an individual, and the cell is in the individual.

55. The method of claim 54 , wherein the individual has been diagnosed with a myeloproliferative disorder.

56. The method of claim 55 , wherein the myeloproliferative disorder is selected from the group consisting of acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), myelodisplastic syndrome (MDS), multiple myeloma, plasmacytoma, and myelofibrosis.

57. The method of claim 53 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 51, 59, and 67, and light chain CDRs of SEQ ID NOs: 75, 83, and 91.

58. The method of claim 57 , wherein the contacting comprises administering the antibody to an individual, wherein the cell is in the individual, and wherein the individual has been diagnosed with a myeloproliferative disorder selected from the group consisting of acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), myelodisplastic syndrome (MDS), multiple myeloma, plasmacytoma, and myelofibrosis.

59. The method of claim 53 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 52, 60, and 68, and light chain CDRs of SEQ ID NOs: 76, 84, and 92.

60. The method of claim 59 , wherein the contacting comprises administering the antibody to an individual, wherein the cell is in the individual, and wherein the individual has been diagnosed with a myeloproliferative disorder selected from the group consisting of acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), myelodisplastic syndrome (MDS), multiple myeloma, plasmacytoma, and myelofibrosis.

61. The method of claim 53 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 53, 61, and 69, and light chain CDRs of SEQ ID NOs: 77, 85, and 93.

62. The method of claim 61 , wherein the contacting comprises administering the antibody to an individual, wherein the cell is in the individual, and wherein the individual has been diagnosed with a myeloproliferative disorder selected from the group consisting of acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), myelodisplastic syndrome (MDS), multiple myeloma, plasmacytoma, and myelofibrosis.

63. The method of claim 53 , wherein the antibody is conjugated to a cytotoxic compound.